The Micra MC1VR01 or Micra AVMC1AVR1 Transcatheter Pacing System (Medtronic, Inc., Minneapolis, MN, USA) has become a major breakthrough as an alternative to standard transvenous pacemakers. The aim of this multi-center study is to assess the clinical outcomes of patients implanted with Micra LLPM in real life, in different clinical scenarios.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
All cause mortality
Timeframe: through study completion, an average of 2 years
Implant complication rates
Timeframe: during and immediately after the intervention
Electrical performance of the pacing system
Timeframe: Through study completion, an average of 2 years
Electrical performance of the pacing system
Timeframe: Through study completion, an average of 2 years
Electrical performance of the pacing system
Timeframe: Through study completion, an average of 2 years
Upgrading with a different pacing system
Timeframe: Through study completion, an average of 2 years